Financial woes reduce AstraZeneca's industry profile

Suffering from a dramatic tailspin in drug sales, AstraZeneca ($AZN) will be shrinking its profile at pharma industry events. The pharma giant has banned all "non-essential" travel overseas and reduced its events team in London from 6 to only two, according to Conference & Incentive Travel. An AstraZeneca spokesperson said that the company is planning far fewer events, so doesn't need the same size staff. The pharma company has been laying off thousands of workers as it tries to restructure its pipeline effort and start winning new drug approvals. Story


Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.